Research advances in treatment of non-alcoholic fatty liver disease
10.3969/j.issn.1001-5256.2015.07.035
- VernacularTitle:非酒精性脂肪性肝病的治疗进展
- Author:
Qiang LI
1
;
Qibin ZHUO
;
Liang CHEN
Author Information
1. First Department of Hepatitis, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
- Publication Type:Research Article
- Keywords:
fatty liver;
therapy;
review
- From:
Journal of Clinical Hepatology
2015;31(7):1135-1139
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic steatohepatitis (NASH). There are metabolic risk factors common to both NAFLD and cardiovascular disease, so patients with NASH have an increased risk of liver-related and cardiovascular death. This articles reviews the most recent advances in the management of NAFLD in five main areas: lifestyle modification, weight loss treatment, therapy for metabolic syndrome, insulin sensitizer and antioxidant pharmacotherapy, and management of end-stage liver disease. It is pointed out that clinicians need to pay more attention to metabolic syndrome in the diagnosis and treatment of NAFLD.
